A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study)

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

(2014) Y Kurokawa et al.   BRITISH JOURNAL OF CANCER

Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis

(2014) A. Tsuburaya et al.   BRITISH JOURNAL OF SURGERY

The Impact of Preoperative Lymph Node Size on Long-Term Outcome Following Curative Gastrectomy for Gastric Cancer

(2012) Masanori Tokunaga et al.   ANNALS OF SURGICAL ONCOLOGY

A Phase II Study of Systemic Chemotherapy with Docetaxel, Cisplatin, and S-1 (DCS) Followed by Surgery in Gastric Cancer Patients with Extensive Lymph Node Metastasis: Japan Clinical Oncology Group Study JCOG1002

(2012) H. Katayama et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Three Definitions of Progression-free Survival in Preoperative Cancer Therapy (JCOG0801-A)

(2012) K. Nakamura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Japanese classification of gastric carcinoma: 3rd English edition

(2011)   Gastric Cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer

(2009) T. Yoshikawa et al.   BRITISH JOURNAL OF SURGERY

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY